Aim: Comparison of efficacy and safety of loteprednol etabonate and bromfenac after phacoemulsification. Material and Methods: Multicenter prospective case series. Consecutive 58 patients (58 eyes) were randomly assigned to the one of the study groups regarding postoperative treatment. Patients in Group I used 0.09% bromfenac 2 times diurnally for 30 days, and patients in Group II used 0.5% loteprednol etabonate 4 times diurnally for 30 days. The laser flare-cell photometry, slit lamp examination, tonometry and optical coherence tomography of macula were performed preoperatively and postoperatively at 1, 7, 30 and 90 days. Results: The distance best corrected visual acuity was 0. 93 in group I and 0.91 in w group II. Laser Flare Photometry, central macular thickness and intraocular pressure was not significantly different during the 3 months of treatment between the groups (p> 0.05). In both groups, there were no abnormalities in routine slit lamp examination of the anterior and posterior segment. Conclusions: The results of the study suggest that topical bromfenac and topical loteprednol etabonate had similar effect on laser flare-cell photometry and foveal thickness in the postoperative period after uneventful phacoemulsification.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.